Application of near-infrared light or blue light source in preparation of equipment for treating diabetes

Abstract

The invention relates to application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes, and belongs to the technical field of photomedicine. The invention provides application of a near-infrared light source or a blue light source in preparation of equipment for treating diabetes. According to the invention, a diabetic rat model is established, near-infrared light and blue light are adopted to carry out phototherapy on diabetic rats, and blood sugar and blood fat related indexes of the diabetic rats and changes of different tissue forms and behaviors of the rats are measured; results show that the near-infrared light and the blue light can effectively improve blood sugar and blood fat related indexes of the rats after phototherapy of the rats, and can also improve tissue morphology and cognitive behaviors of the diabetic rats, which indicates that the phototherapy of the near-infrared light or the blue light has the effects of treating diabetic blood sugar and cognition, can reduce dependence of patients on medicines, and can improve the curative effect of the patients on diabetes mellitus. And new experimental basis and theoretical support are provided for clinical non-drug intervention of diabetes.

Description

Technical Field

[0001] This invention relates to the field of photomedicine technology, and more particularly to the application of near-infrared or blue light sources in the preparation of devices for treating diabetes. Background Technology

[0002] In recent years, the global incidence of diabetes has been rising steadily, becoming one of the most serious chronic metabolic diseases threatening human health. Diabetic patients often experience a range of metabolic problems, including disordered glucose metabolism, dyslipidemia, and insulin resistance. If poorly controlled over a long period, these conditions can easily lead to various complications such as cardiovascular disease, kidney disease, and neuropathy, not only reducing patients' quality of life but also increasing the social burden on healthcare.

[0003] Phototherapy, as an emerging physical intervention, has seen increasing research in the field of diabetes treatment in recent years. Its core mechanism is based on photobiomodulation (PBM) (also known as low-level laser therapy, LLLT), which can produce positive intervention effects on diabetes and its complications by regulating cellular metabolic processes (such as improving mitochondrial function, inhibiting oxidative stress response, and regulating the balance of inflammatory factors). However, relevant research is lacking.

[0004] Based on this, the present invention is proposed. Summary of the Invention

[0005] The purpose of this invention is to provide the application of near-infrared light or blue light sources in the preparation of devices for treating diabetes, so as to solve the problem of the lack of phototherapy for diabetes treatment in the prior art.

[0006] To achieve the above-mentioned objectives, the present invention provides the following technical solution: This invention provides the application of near-infrared light or blue light sources in the preparation of devices for treating diabetes.

[0007] This invention provides the application of near-infrared or blue light sources in the preparation of devices for reducing fasting blood glucose levels in diabetic patients.

[0008] This invention provides the application of near-infrared or blue light sources in the preparation of equipment for reducing glycated hemoglobin levels in diabetes.

[0009] This invention provides the application of near-infrared or blue light sources in the preparation of devices for reducing cholesterol levels in diabetes.

[0010] This invention provides the application of near-infrared or blue light sources in the preparation of devices for reducing triglyceride levels in diabetes.

[0011] This invention provides the application of near-infrared or blue light sources in the preparation of devices for improving the metabolism of low and / or high-density lipoprotein cholesterol in diabetic patients.

[0012] This invention provides the application of near-infrared or blue light sources in the preparation of equipment for reducing the content of free fatty acids in diabetes.

[0013] Preferably, the near-infrared light source emits near-infrared light with a wavelength of 800~810nm; the blue light source emits blue light with a wavelength of 460~480nm.

[0014] Preferably, the output power density of the near-infrared light source is 1~30 mW / cm². 2 The light intensity of the blue light source is 30~350 lux.

[0015] The present invention has the following technical effects and advantages: This invention established a diabetic rat model and studied the differences in the regulatory effects of phototherapy of different wavelengths on the metabolic levels of diabetic rats. Near-infrared light and blue light were used to treat diabetic rats. By measuring blood glucose and lipid-related indicators, as well as changes in different tissue morphology and behavior of the rats, the results showed that phototherapy with near-infrared light and blue light could effectively improve the levels of fasting blood glucose, glycated hemoglobin, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and free fatty acids in rats. It could also improve the tissue morphology and cognitive behavior of diabetic rats, indicating that phototherapy with near-infrared light or blue light has therapeutic effects on blood glucose and cognition in diabetic patients, and can reduce patients' dependence on drugs. This provides new experimental evidence and theoretical support for the clinical non-drug intervention of diabetes. Attached Figure Description

[0016] Figure 1 The results of fasting blood glucose levels in rats in different treatment groups; Figure 2 Fasting plasma glucose levels in rats from different treatment groups at different time points; Figure 3 The total blood glucose levels of rats in different treatment groups over a certain period of time; Figure 4 Glycated hemoglobin levels in rats from different treatment groups; Figure 5 Total cholesterol levels in rats from different treatment groups; Figure 6 Triglyceride levels in rats from different treatment groups; Figure 7 The high-density lipoprotein cholesterol levels in rats of different treatment groups; Figure 8 Low-density lipoprotein cholesterol levels in rats under different treatment groups; Figure 9 The levels of free fatty acids in rats from different treatment groups; Figure 10 The movement trajectories of rats in open field experiments in different treatment groups; Figure 11 HE staining images of pancreatic islet tissue from rats in different treatment groups; Figure 12 HE staining images of retinal tissue from rats in different treatment groups; Figure 13 HE staining images of hippocampal tissue from rats in different treatment groups; Figure 14 TUNEL staining images of hippocampal tissue from rats in different treatment groups. Detailed Implementation

[0017] This invention provides the application of near-infrared light or blue light sources in the preparation of devices for treating diabetes.

[0018] This invention provides the application of near-infrared or blue light sources in the preparation of devices for reducing fasting blood glucose levels in diabetic patients.

[0019] This invention provides the application of near-infrared or blue light sources in the preparation of equipment for reducing glycated hemoglobin levels in diabetes.

[0020] This invention provides the application of near-infrared or blue light sources in the preparation of devices for reducing cholesterol levels in diabetes.

[0021] This invention provides the application of near-infrared or blue light sources in the preparation of devices for reducing triglyceride levels in diabetes.

[0022] This invention provides the application of near-infrared or blue light sources in the preparation of devices for improving the metabolism of low and / or high-density lipoprotein cholesterol in diabetic patients.

[0023] This invention provides the application of near-infrared or blue light sources in the preparation of equipment for reducing the content of free fatty acids in diabetes.

[0024] In this invention, the near-infrared light source emits near-infrared light with a wavelength of 800~810nm, preferably 808nm; the blue light source emits blue light with a wavelength of 460~480nm, preferably 468nm.

[0025] In this invention, the output power density of the near-infrared light source is 1~30 mW / cm². 2 The preferred value is 20mW / cm 2 The illuminance of the blue light source is 30~350 lux, preferably 300 lux.

[0026] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.

[0027] Example 1: Establishment and grouping of a diabetic rat model

[0028] Healthy male SD rats (weighing 200-220g) were selected and, after 1 week of acclimatization feeding, were randomly divided into a normal control group (normal group) and a diabetic model group (diabetic group).

[0029] The diabetic model group (diabetic group) rats were established by intraperitoneal injection of streptozotocin (STZ, dissolved in 0.1 mol / L citrate-sodium citrate buffer, pH 4.5) at a dose of 60 mg / kg; the normal control group (normal group) rats were intraperitoneally injected with an equal volume of citrate-sodium citrate buffer.

[0030] 72 hours after STZ injection, fasting blood glucose (FBG) was measured by blood collection from the tail vein. Rats with FBG ≥ 16.7 mmol / L were considered to have successfully established a diabetic model.

[0031] The successfully modeled diabetic rats were randomly divided into three groups: the diabetic model control group (diabetic group), the near-infrared light intervention group (808nm group), and the blue light intervention group (468nm group), with 8 rats in each group; and the normal control group (normal group) with 6 rats.

[0032] Example 2: Effects of different light sources on rats

[0033] 1. Phototherapy equipment

[0034] The near-infrared light intervention group (808nm group) used an animal phototherapy box with a near-infrared light source emitting a wavelength of 808nm and an output power density of 20mW / cm². 2 The blue light intervention group (468nm group) used an animal phototherapy box with a blue light source emitting a wavelength of 468nm and a light intensity of 300 lux.

[0035] 2. Irradiation time and frequency

[0036] The near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) were irradiated once in the morning and once in the evening, each time for 30 minutes, for 7 consecutive days a week, for a total irradiation cycle of 4 weeks.

[0037] 3. Detection indicators

[0038] All data obtained were processed using SPSS 26.0 statistical software. Quantitative data are expressed as mean ± standard deviation, and one-way ANOVA was used for comparisons among multiple groups. P<0.05 indicates a statistically significant difference. Compared with the normal control group (normal group): "express P <0.05, "express P <0.01, "express P <0.001; Compared with the diabetes model group (diabetes group): "#" indicates P <0.05, "##" indicates P <0.01, "###" indicates P <0.001.

[0039] 3.1 Blood glucose related indicator testing

[0040] 3.1.1 Measurement of fasting blood glucose (FBG)

[0041] Day 0 was the day before the start of the experiment. On days 0 and 28 of the intervention, blood was collected from the tail vein of rats in different treatment groups to measure fasting blood glucose (FBG). The results of fasting blood glucose levels in the different treatment groups are as follows: Figure 1 As shown.

[0042] according to Figure 1 It was found that before the intervention (day 0), the FBG of the normal control group (normal group) remained within the normal physiological range (approximately 4 mmol / L); the FBG of the diabetes model group (diabetes group), the near-infrared light intervention group (808nm group), and the blue light intervention group (468nm group) all significantly increased to above 20 mmol / L, and the FBG levels of all three groups were significantly higher than those of the normal group, confirming the successful establishment of the diabetes model. After the intervention (day 28), the FBG of the diabetes model group (diabetes group) was significantly higher than that of the normal control group (normal group); while the FBG of the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) showed a significant decreasing trend compared with before the intervention, and were significantly lower than those of the diabetes model group (diabetes group). Among them, the FBG of the near-infrared light intervention group (808nm group) decreased to approximately 5 mmol / L, and the FBG of the blue light intervention group (468nm group) decreased to approximately 8 mmol / L. The results showed that both near-infrared light with a wavelength of 808 nm and blue light with a wavelength of 468 nm could effectively reduce fasting blood glucose levels in diabetic rats, and near-infrared light with a wavelength of 808 nm had a better hypoglycemic effect.

[0043] 3.1.2 Glucose Tolerance Test (GTT)

[0044] After the experiment, rats in each group were subjected to a glucose tolerance test, and the specific method is as follows: Rats were fasted for 12 hours and then injected intraperitoneally with 2 g / kg glucose. Fasting plasma glucose (FPG) was measured at 0, 30, 60, 90, and 120 min, and the area under the curve (AUC) was calculated. Total ), the result is as follows Figure 2 and Figure 3 As shown, Figure 2 The fasting plasma glucose levels of rats in different treatment groups at different time points. Figure 3 The total blood glucose level of rats in different treatment groups over a certain period of time.

[0045] The glucose tolerance test (GTT) can be used to assess the ability to regulate glucose metabolism, based on... Figure 2 It can be seen that before the intervention (0 min), the FPG of the normal control group (normal group) was within the normal range, while the FPG of the diabetes model group (diabetes group) was significantly increased. There was no significant difference in FPG between the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) and the DM group. After the intervention, at the peak glucose load at 30 min, the FPG of the diabetes model group surged to above 20 mmol / L and remained at a high value, while the peak FPG of the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) was significantly lower than that of the diabetes model group (diabetes group). As time prolongs (60~120 min), the FPG of the normal control group (normal group) gradually returned to the normal level, while the FPG of the diabetes model group (diabetes group) remained at around 20 mmol / L. The FPG of the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) showed a continuous downward trend, and the rate of decline and the final level of the near-infrared light intervention group (808nm group) were better than those of the blue light intervention group (468nm group). The above results indicate that both near-infrared light with a wavelength of 808 nm and blue light with a wavelength of 468 nm can improve glucose tolerance in diabetic rats and enhance the body's dynamic regulation of blood glucose, with near-infrared light with a wavelength of 808 nm showing a more significant improvement effect.

[0046] AUC Total It can reflect the overall level of blood glucose exposure over a period of time; the higher the value, the more severe the glucose metabolism disorder. According to... Figure 3 It can be seen that after glucose ingestion, both near-infrared light with a wavelength of 808 nm and blue light with a wavelength of 468 nm can effectively reduce the AUC of diabetic rats. Total It can alleviate glucose metabolism disorders, and the improvement effect of near-infrared light with a wavelength of 808nm is even better.

[0047] 3.1.3 Determination of Glycated Hemoglobin (HbA1c)

[0048] After the experiment, blood samples were collected and the glycated hemoglobin (HbA1c) levels of rats in different treatment groups were detected by high-performance liquid chromatography (HPLC). The glycated hemoglobin levels of rats in different treatment groups are shown below. Figure 4 As shown.

[0049] Elevated HbA1c levels indicate poor long-term blood glucose control, according to Figure 4 It can be seen that both near-infrared light with a wavelength of 808nm and blue light with a wavelength of 468nm can improve the long-term blood glucose control in diabetic rats, and blue light has a more prominent effect on downregulating HbA1c. This result complements the differentiated effects of phototherapy of different wavelengths on blood glucose regulation.

[0050] 3.2 Detection of blood lipid-related indicators

[0051] After the experiment, blood was collected from the abdominal aorta of rats in each group, and serum was separated by centrifugation. The levels of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and free fatty acids (FFA) in different treatment groups were detected using a fully automated biochemical analyzer. The results are as follows: Figures 5-9 As shown, Figure 5 The total cholesterol levels in rats in different treatment groups, Figure 6 Triglyceride levels in rats of different treatment groups Figure 7 The high-density lipoprotein cholesterol levels in rats of different treatment groups, Figure 8 The low-density lipoprotein cholesterol levels in rats of different treatment groups, Figure 9 The levels of free fatty acids in rats under different treatment groups.

[0052] Total cholesterol (TC) is a core indicator reflecting lipid metabolism status; elevated TC levels suggest lipid metabolism disorders and are a risk factor for diabetic complications. According to... Figure 5 It was found that TC was significantly elevated in the diabetic model group (diabetic group) compared with the normal control group (normal group), indicating that rats in the diabetic state had obvious lipid metabolism disorders. Compared with the diabetic model group (diabetic group), TC in the near-infrared light intervention group (808nm group) remained at a high level without significant change, while TC in the blue light intervention group (468nm group) was significantly reduced. The results show that blue light with a wavelength of 468nm can effectively improve the total cholesterol metabolism disorder in diabetic rats, while near-infrared light with a wavelength of 808nm has no obvious regulatory effect on TC. The reason may be that there are specific differences in the target sites of different wavelengths of light. Blue light with a wavelength of 808nm may reduce cholesterol synthesis by inhibiting liver lipid synthesis-related enzymes, while the effect of near-infrared light with a wavelength of 468nm is more focused on glucose metabolism-related pathways, and its regulatory effect on lipid metabolism is relatively weak.

[0053] Triglycerides (TG) are a key indicator of lipid metabolism; elevated levels usually suggest lipid metabolism disorders and are closely related to the occurrence of cardiovascular complications in diabetes. According to... Figure 6 It was found that TG levels were significantly elevated in the diabetic model group (diabetic group) compared to the normal control group (normal group), indicating that there is significant lipid metabolism disorder in diabetic rats. Compared to the diabetic model group (diabetic group), TG levels were significantly reduced in both the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group), with the blue light intervention group (468nm group) showing better results. This result indicates that both near-infrared light with a wavelength of 808nm and blue light with a wavelength of 468nm can improve triglyceride metabolism disorder in diabetic rats. The reason may be that both wavelengths of light can reduce TG levels by regulating the balance of lipolysis and lipid synthesis in adipocytes or improving the lipid transport function of the liver, and the regulatory effect of blue light is relatively more prominent.

[0054] according to Figure 7 It was found that, compared with the normal control group (normal group), the high-density lipoprotein cholesterol (HDL) level in the diabetic model group (diabetic group) showed an increasing trend, suggesting that HDL metabolism was disordered in rats under diabetic conditions. Compared with the diabetic model group (diabetic group), the HDL levels in the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) were reduced. This result indicates that near-infrared light with a wavelength of 808nm and blue light with a wavelength of 468nm have an ameliorative effect on HDL disorder.

[0055] Low-density lipoprotein cholesterol (LDL) is an "atherosclerotic lipoprotein." Elevated LDL levels promote cholesterol deposition in blood vessel walls, increasing the risk of cardiovascular complications and serving as a negative indicator of lipid metabolism disorders. According to... Figure 8 The results showed that LDL levels were significantly elevated in the diabetic model group (diabetic group) compared to the normal control group (normal group), indicating that rats in a diabetic state exhibited significant atherogenic lipid metabolism disorders. Compared to the diabetic model group (diabetic group), LDL levels were lower in the near-infrared light intervention group (808nm group) and significantly lower in the blue light intervention group (468nm group). These results suggest that blue light at a wavelength of 468nm can effectively reduce LDL levels in diabetic rats and improve atherogenic lipid metabolism disorders; while near-infrared light at a wavelength of 808nm had little effect on LDL regulation. This may be because blue light can promote LDL clearance and metabolism by regulating the expression and activity of hepatic LDL receptors, while near-infrared light targets glucose metabolism pathways and lacks specificity in regulating LDL metabolism.

[0056] Free fatty acids (FFAs) are products of fat breakdown. Elevated levels of FFAs can worsen insulin resistance and interfere with glucose and lipid metabolism, making them a significant driver of metabolic disorders in diabetes. According to... Figure 9 The results showed that, compared with the normal control group (normal group), the FFA level in the diabetic model group (diabetic group) was significantly increased, indicating that lipolysis in rats under diabetic conditions was abnormally active, and FFA accumulation led to metabolic disorders. Compared with the diabetic model group (diabetic group), the FFA level in the near-infrared light intervention group (808nm group) was reduced; the FFA level in the blue light intervention group (468nm group) was significantly reduced, which was significantly better than that in the near-infrared light intervention group (808nm group). The results indicate that near-infrared light with a wavelength of 808nm can mildly improve FFA accumulation in diabetic rats, while blue light with a wavelength of 468nm can more significantly inhibit lipolysis and reduce FFA release. The mechanism may be that blue light inhibits fat mobilization by regulating the activity of lipolysis-related enzymes (such as hormone-sensitive lipase) in adipocytes, thereby reducing FFA levels, while the direct regulatory effect of near-infrared light on adipocytes is relatively weak.

[0057] 3.3 Open field experiment of rats in different treatment areas

[0058] After the intervention, open field tests were performed on rats in each group, and the movement trajectories of the rats in each group were recorded. The movement trajectories of rats in different treatment groups in the open field test are as follows: Figure 10 As shown.

[0059] according to Figure 10 It was found that, compared with the normal control group (normal group), the movement trajectory of rats in the diabetic model group (diabetic group) decreased in the central region, indicating that the exploration ability of rats in the diabetic state was significantly reduced; compared with the diabetic model group (diabetic group), the movement trajectory of rats in the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) increased in the central region; the results show that near-infrared light with a wavelength of 808nm and blue light with a wavelength of 468nm have an ameliorative effect on anxiety and depression in diabetic rats.

[0060] 3.4 Tissue staining analysis of rats in different treatment groups

[0061] After the intervention, rats in each group were sacrificed, and pancreatic islet tissue, retinal tissue, and hippocampal tissue were collected. The pancreatic islet tissue, retinal tissue, and hippocampal tissue were stained with hematoxylin and eosin (HE), and the hippocampal tissue was then stained with TUNEL. The results are as follows: Figures 11-14 As shown, Figure 11 HE staining images of pancreatic islet tissue from rats in different treatment groups. Figure 12 HE staining images of retinal tissue from rats in different treatment groups. Figure 13 HE staining images of hippocampal tissue from rats in different treatment groups. Figure 14 TUNEL staining images of hippocampal tissue from rats in different treatment groups.

[0062] according to Figure 11 It was found that, compared with the normal control group (normal group), the islet structure of the diabetic model group (diabetic group) was loose, the cell arrangement was disordered, and the number of vacuolar lesions in the islets was increased, indicating that the islet tissue of rats in diabetic state had obvious pathological damage. Compared with the diabetic model group (diabetic group), the islet structure of the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) was more complete, the cell arrangement was more regular, and the vacuolar lesions were significantly reduced. This result shows that near-infrared light with a wavelength of 808nm and blue light with a wavelength of 468nm have an ameliorative effect on the pathological damage of islet tissue in diabetic rats.

[0063] according to Figure 12 The results showed that the retinal structure of rats in the normal control group (normal group) was intact, and the cells in each layer were arranged in a regular manner. The retina of rats in the diabetic model group (diabetic group) showed obvious pathological damage, manifested as disordered cell layer structure and increased intercellular spaces. In contrast, the retinal structure of the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) was significantly improved compared to the normal control group (normal group), with more regular cell arrangement and significantly reduced damage. This result indicates that 808nm near-infrared light and 468nm blue light have no damaging effect on the rat retina and can effectively improve retinal pathological damage in rats with diabetes.

[0064] according to Figure 13 It was found that, compared with the normal control group (normal group), the hippocampal tissue of the diabetic model group (diabetic group) showed disordered cell arrangement, increased intercellular spaces, and obvious vacuolar degeneration, indicating significant pathological damage to the hippocampal tissue of rats in a diabetic state. Compared with the diabetic model group (diabetic group), the hippocampal cells of the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) were more regularly arranged, with smaller intercellular spaces and significantly reduced vacuolar degeneration. This result indicates that near-infrared light with a wavelength of 808nm and blue light with a wavelength of 468nm have an ameliorative effect on the pathological damage of hippocampal tissue in diabetic rats.

[0065] according to Figure 14 The results showed that, compared with the normal control group (normal group), the number of TUNEL-positive cells (fluorescently stained apoptotic cells) in the hippocampus of the diabetic model group (diabetic group) was significantly increased, indicating that the apoptosis level of hippocampal neurons in diabetic rats was significantly increased. Compared with the diabetic model group (diabetic group), the number of TUNEL-positive cells in the near-infrared light intervention group (808nm group) and the blue light intervention group (468nm group) was significantly reduced. This result indicates that near-infrared light with a wavelength of 808nm and blue light with a wavelength of 468nm have an inhibitory effect on excessive apoptosis of hippocampal neurons in diabetic rats.

[0066] In conclusion, irradiation of diabetic rats with near-infrared light (808 nm) or blue light (468 nm) can effectively reduce their fasting blood glucose levels, improve glucose tolerance, enhance the body's dynamic regulation of blood glucose, alleviate symptoms of disordered glucose, cholesterol, and triglyceride metabolism, regulate low- and / or high-density lipoprotein cholesterol metabolism, and reduce free fatty acid levels. These findings collectively demonstrate that near-infrared light (808 nm) or blue light (468 nm) has a significant phototherapy effect on diabetes.

[0067] As can be seen from the above embodiments, this invention provides the application of near-infrared light or blue light sources in the preparation of devices for treating diabetes. This invention established a diabetic rat model and studied the differences in the regulatory effects of different wavelengths of phototherapy on the metabolic levels of diabetic rats. Near-infrared light and blue light were used to treat diabetic rats. By measuring blood glucose and lipid-related indicators, as well as changes in different tissue morphology and behavior, the results showed that near-infrared light and blue light phototherapy effectively improved the levels of fasting blood glucose, glycated hemoglobin, cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and free fatty acids in rats. It also improved the tissue morphology and cognitive behavior of diabetic rats, indicating that near-infrared light or blue light phototherapy has therapeutic effects on blood glucose and cognition in diabetes, reducing patients' dependence on drugs and providing new experimental evidence and theoretical support for clinical non-drug interventions for diabetes.

[0068] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.

Claims

1. Application of near-infrared or blue light sources in the preparation of devices for treating diabetes.

2. Application of near-infrared or blue light sources in the preparation of devices to lower fasting blood glucose levels in diabetic patients.

3. Application of near-infrared or blue light sources in the preparation of equipment to reduce glycated hemoglobin levels in diabetes.

4. Application of near-infrared or blue light sources in the preparation of equipment to lower cholesterol levels in diabetes.

5. Application of near-infrared or blue light sources in the preparation of equipment to reduce triglyceride levels in diabetes.

6. Application of near-infrared or blue light sources in the preparation of devices to improve the metabolism of low and / or high-density lipoprotein cholesterol in diabetic patients.

7. Application of near-infrared or blue light sources in the preparation of equipment to reduce the content of free fatty acids in diabetes.

8. The application according to any one of claims 1 to 7, characterized in that, The near-infrared light source emits near-infrared light with a wavelength of 800~810nm; the blue light source emits blue light with a wavelength of 460~480nm.

9. The application according to any one of claims 1 to 7, characterized in that, The output power density of the near-infrared light source is 1~30mW / cm². 2 The light intensity of the blue light source is 30~350 lux.

Images